BIIB Earnings: Biogen Q1 2025 adj. profit drops despite higher revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year decrease in adjusted profit for the first quarter of 2025,...
Health Care
Infographic: How Eli Lilly (LLY) performed in Q1 2025
Eli Lilly and Company (NYSE: LLY) reported its first quarter 2025 earnings results today. Worldwide revenue was $12.73 billion, up...
Earnings: CVS Health Q1 2025 revenue and profit beat estimates
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) reported higher revenues and adjusted profit for the first quarter of 2025. The...
Key highlights from Pfizer’s (PFE) Q1 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its first quarter 2025 earnings results today. Revenues decreased 8% year-over-year to $13.7 billion. GAAP...
Earnings Summary: Revvity (RVTY) reports higher revenue and earnings for Q1 2025
Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, on Monday reported an increase in revenue and...
Earnings Summary: HCA Healthcare reports higher Q1 2025 revenue and profit
HCA Healthcare, Inc. (NYSE: HCA) on Friday reported an increase in revenues and net income for the first quarter of...
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The...
Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops
Bristol Myers Squibb (NYSE: BMY) reported net profit for the first quarter of 2025, compared to a loss last year....
MRK Earnings: Merck & Co. Q1 adj. profit rises, beats estimates
Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while...
Earnings: Intuitive Surgical (ISRG) reports higher revenue and profit for Q1 2025
Healthcare technology company Intuitive Surgical Inc. (NASDAQ: ISRG) Wednesday reported a sharp increase in revenue and adjusted earnings for the...
Earnings: Highlights of Thermo Fisher Scientific’s (TMO) Q1 2025 report
Thermo Fisher Scientific Inc. (NYSE: TMO) on Wednesday announced financial results for the first quarter of 2025, reporting a modest...
Infographic: How UnitedHealth Group (UNH) performed in Q1 2025
UnitedHealth Group (NYSE: UNH) reported its first quarter 2025 earnings results today. Total revenues were $109.6 billion compared to $99.8...
Abbott Laboratories (ABT) Q1 2025 Earnings: Key financials and quarterly highlights
Abbott Laboratories (NYSE: ABT) reported its first quarter 2025 earnings results today. Total sales increased 4% year-over-year to $10.35 billion....
JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q1 2025 financial results
Johnson & Johnson (NYSE: JNJ) reported its first quarter 2025 earnings results today. Reported sales increased 2.4% year-over-year to $21.9...
UNH Earnings Preview: Will UnitedHealth’s Q1 earnings beat expectations?
Like many insurance companies, UnitedHealth Group (NYSE: UNH) generally demonstrates the ability to remain relatively resilient during economic downturns, mainly...
Deals and R&D in focus as Johnson & Johnson gears up for Q1 earnings
For Johnson & Johnson (NYSE: JNJ), investments in its pipeline and exiting lower priority businesses remain central to its strategy...
Walgreens Boots Alliance (WBA) Q2 2025 Earnings: Key financials and quarterly highlights
Walgreens Boots Alliance (NASDAQ: WBA) reported its second quarter 2025 earnings results today. Sales increased 4.1% year-over-year to $38.6 billion....
AngioDynamics (ANGO) Q3 2025 loss narrows; sales down 4%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) Wednesday reported a narrower net loss for the third quarter of 2025. Revenues...
Walgreens Boots Alliance set to report Q2 earnings. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a market leader in health and wellness services, is preparing to report second-quarter results,...
OS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul Romness
OS Therapies (NYSE: OSTX) is a cancer immunotherapy company engaged in the development of new treatments for osteosarcoma and other...
Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance
Quest Diagnostics Incorporated (NYSE: DGX), a provider of diagnostic information services, has reaffirmed its outlook for fiscal 2025 and provided...